Starling Oncology STLN
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on STLN
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on STLN.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
STLN at a glance
STLN last changed hands at $3.62 (down 45.97%). At $369.21M, Starling Oncology is ranked #3728 by size among the 3753 stocks on BeStock.
The 52-week range is $2.32 to $7.13. Today's price is about 27% of the way from the low to the high. Holders are ahead 2.1% over twelve months, but down 41.2% across the last three months.
On the chart it has slipped under both the 50-day ($6.43) and 200-day ($4.76) moving averages; RSI is 25, which some call oversold, and the last 30 sessions moved at roughly 189% annualized volatility.
In the quarter ended Jun 2026 the company brought in $161.28M of revenue, up 34.6% from a year earlier, and a net loss of $9.79M.
2 analysts follow the stock and the average call is "buy". The mean target, $10.00, sits 176.2% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 3 factors below, ranked against the 3741 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
2 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
STLN is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (203.8% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $10.00, 176.2% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $6.73, so shares trade 46.2% below that estimate. On earnings multiple, it sits in the 27th percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -44.1% | Bearish |
| Price vs 50-day average | -43.7% | Bearish |
| Price vs 200-day average | -24.0% | Bearish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 25.3 | Neutral |
| MACD (12,26,9) | -0.21 | Bearish |
| Bollinger band position | -51% | Neutral |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 6, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
How STLN ranks on BeStock
Ranks are among the 3,741 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
STLN stock: common questions
Where is STLN trading right now?
$3.62 is the latest print for STLN, a move of -45.97% against yesterday's close of $6.70. Today's low and high so far: $3.35 and $6.43.
How big is Starling Oncology?
Equity value comes to $369.21M at the current price. By that measure it is number 3728 of the 3753 names in our coverage.
Where does STLN sit in its 52-week range?
The year's floor is $2.32 and the ceiling $7.13. Shares are 49.2% away from that ceiling.
Does STLN send cash back through a dividend?
Our data shows no dividend paid by Starling Oncology over the trailing twelve months.
Do Wall Street analysts like STLN?
Of 2 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $10.00, with the most cautious at $9.00 and the most optimistic at $11.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on STLN.
Sign in to join the discussion.